Australia's Island Pharma gains on clinical trial progress for dengue drug

Island Pharmaceuticals

04/01/2022 24:40

** Shares of the anti-viral drug developer  ILA.AX  rise as
much as 5.9% to A$0.270, post their biggest intraday pct gain
since Nov 26 
    ** Island Pharma signs clinical trial support services deal
with ICON Government and Public Health Solutions (GPHS) for co's
upcoming ISLA-101 Phase 2a PEACH study  urn:newsml:reuters.com:*:nASXbVWn5n
    * GPHS provides full-service clinical development and
staffing services across multiple agencies in the U.S. govt 
    ** ISLA-101 prevents and treats dengue fever and other
mosquito-borne diseases and the PEACH trial is a Phase 2a,
placebo-controlled study for examination of an antiviral in a
dengue challenge model - Island Pharma 
    ** More than 63,000 shares change hands as compared with the
30-day average volume of ~87,000 shares  


 (Reporting by Roushni Nair in Bengluru)
 ((Roushni.Nair@thomsonreuters.com;))